Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Habte A. Yimer"'
Autor:
Jeff P. Sharman, Peter Trask, Yeung-Chul Mun, Anthony Masaquel, Habte A. Yimer, Alexey V. Danilov, John M. Burke, Sunil Babu, Jia Li, Michael Boxer
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:121-128
Introduction: Longitudinal changes in health-related quality of life (HRQoL) are important in patients with chronic lymphocytic leukemia (CLL). GIBB (NCT02320487) is an open-label, single-arm phase II study of obinutuzumab (GA101; G) in combination w
Autor:
Stephen J. Noga, Karin Choquette, Habte A. Yimer, Kimberly Bogard, Jennifer Clayton, Joshua Richter, Kirsten Stuber, Saulius Girnius, Sudhir Manda, Presley Whidden, Dasha Cherepanov
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:HSR21-070
Autor:
M.C. Liu, G.R. Oxnard, E.A. Klein, C. Swanton, M.V. Seiden, Minetta C. Liu, Geoffrey R. Oxnard, Eric A. Klein, David Smith, Donald Richards, Timothy J. Yeatman, Allen L. Cohn, Rosanna Lapham, Jessica Clement, Alexander S. Parker, Mohan K. Tummala, Kristi McIntyre, Mikkael A. Sekeres, Alan H. Bryce, Robert Siegel, Xuezhong Wang, David P. Cosgrove, Nadeem R. Abu-Rustum, Jonathan Trent, David D. Thiel, Carlos Becerra, Manish Agrawal, Lawrence E. Garbo, Jeffrey K. Giguere, Ross M. Michels, Ronald P. Harris, Stephen L. Richey, Timothy A. McCarthy, David M. Waterhouse, Fergus J. Couch, Sharon T. Wilks, Amy K. Krie, Rama Balaraman, Alvaro Restrepo, Michael W. Meshad, Kimberly Rieger-Christ, Travis Sullivan, Christine M. Lee, Daniel R. Greenwald, William Oh, Che-Kai Tsao, Neil Fleshner, Hagen F. Kennecke, Maged F. Khalil, David R. Spigel, Atisha P. Manhas, Brian K. Ulrich, Philip A. Kovoor, Christopher Stokoe, Jay G. Courtright, Habte A. Yimer, Timothy G. Larson, Charles Swanton, Michael V. Seiden, Steven R. Cummings, Farnaz Absalan, Gregory Alexander, Brian Allen, Hamed Amini, Alexander M. Aravanis, Siddhartha Bagaria, Leila Bazargan, John F. Beausang, Jennifer Berman, Craig Betts, Alexander Blocker, Joerg Bredno, Robert Calef, Gordon Cann, Jeremy Carter, Christopher Chang, Hemanshi Chawla, Xiaoji Chen, Tom C. Chien, Daniel Civello, Konstantin Davydov, Vasiliki Demas, Mohini Desai, Zhao Dong, Saniya Fayzullina, Alexander P. Fields, Darya Filippova, Peter Freese, Eric T. Fung, Sante Gnerre, Samuel Gross, Meredith Halks-Miller, Megan P. Hall, Anne-Renee Hartman, Chenlu Hou, Earl Hubbell, Nathan Hunkapiller, Karthik Jagadeesh, Arash Jamshidi, Roger Jiang, Byoungsok Jung, TaeHyung Kim, Richard D. Klausner, Kathryn N. Kurtzman, Mark Lee, Wendy Lin, Jafi Lipson, Hai Liu, Qinwen Liu, Margarita Lopatin, Tara Maddala, M. Cyrus Maher, Collin Melton, Andrea Mich, Shivani Nautiyal, Jonathan Newman, Joshua Newman, Virgil Nicula, Cosmos Nicolaou, Ongjen Nikolic, Wenying Pan, Shilpen Patel, Sarah A. Prins, Richard Rava, Neda Ronaghi, Onur Sakarya, Ravi Vijaya Satya, Jan Schellenberger, Eric Scott, Amy J. Sehnert, Rita Shaknovich, Avinash Shanmugam, K.C. Shashidhar, Ling Shen, Archana Shenoy, Seyedmehdi Shojaee, Pranav Singh, Kristan K. Steffen, Susan Tang, Jonathan M. Toung, Anton Valouev, Oliver Venn, Richard T. Williams, Tony Wu, Hui H. Xu, Christopher Yakym, Xiao Yang, Jessica Yecies, Alexander S. Yip, Jack Youngren, Jeanne Yue, Jingyang Zhang, Lily Zhang, Lori (Quan) Zhang, Nan Zhang, Christina Curtis, Donald A. Berry
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology
Background Early cancer detection could identify tumors at a time when outcomes are superior and treatment is less morbid. This prospective case-control sub-study (from NCT02889978 and NCT03085888) assessed the performance of targeted methylation ana
Autor:
Jay Courtright, Nikolaus S. Trede, Daanish Hoda, Habte A. Yimer, Paul Shaughnessy, J. Essell, Don A. Stevens, James Lymp, J. C. Varela, Suzanne R. Fanning, C.R. Bachier, Mohamad Cherry, Marina Youssef, Jeffrey P. Sharman, J. E. Godwin, Michael B. Maris, B. Mattar
Publikováno v:
Hematological Oncology. 39
Autor:
Juan C. Varela, Mohamad Cherry, Nikolaus S. Trede, Cesar O. Freytes, Don A. Stevens, Suzanne R. Fanning, Daanish Hoda, Bassam I. Mattar, James Lymp, Michael B. Maris, Habte A. Yimer, John E. Godwin, Carlos Bachier, James Essell, Marina Youssef, Jay Courtright
Publikováno v:
Blood. 136:50-52
Background: Currently approved CAR T cell therapies are generally administered as inpatient treatment at university medical centers due to concerns about the frequency, onset, severity, and management of AEs, including cytokine release syndrome (CRS)
Autor:
Robert M. Rifkin, Habte A. Yimer, Dasha Cherepanov, Jack Aiello, Roger M. Lyons, Sudhir Manda, Presley Whidden, Vickie Lu, Kimberly Bogard, Saulius Girnius, Joshua Richter, Stephen J. Noga
Publikováno v:
Blood. 136:2-4
Background Long-term PI-based treatment is associated with improved outcomes in MM. Nonetheless, prolonged therapy with parenteral PIs (e.g. bortezomib) can be challenging in the real world, with median duration of therapy (DOT) of 4-7 months. Barrie
Autor:
Jason M. Melear, Thomas S. Lin, Keqin Qi, Yana Lutska, Mohit Narang, Ming Qi, Edward A. Faber, William I. Bensinger, Habte A. Yimer, Robert M. Rifkin, Sriya Gunawardena, John M. Burke, Don A. Stevens, Jon Ukropec
Publikováno v:
British Journal of Haematology
Summary This United States community study evaluated the combination of daratumumab, bortezomib, cyclophosphamide and dexamethasone (D‐VCd) in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). Patients received 4–8 indu
Autor:
John M. Burke, Michael Boxer, Habte A. Yimer, Gibb study investigators, Sunil Babu, Yeung-Chul Mun, Jeff P. Sharman, Alexey V. Danilov, Jia Li
Publikováno v:
Leukemialymphoma. 62(4)
The single-arm, multicenter, phase 2 GIBB study (NCT02320487) investigated bendamustine plus obinutuzumab (BG) in previously untreated CLL. Patients (N = 102) received six cycles of intravenous obi...
Autor:
Carlos Bachier, Mohamad Cherry, Nikolaus S. Trede, Michael B. Maris, Habte A. Yimer, Bassam I. Mattar, Daanish Hoda, James Essell, James Lymp, Marina Youssef, Cesar O. Freytes, Suzanne R. Fanning, Don A. Stevens, Jay Courtright, John E. Godwin, Juan Carlos Varela
Publikováno v:
Transplantation and Cellular Therapy. 27:S203-S204
Autor:
Ralph V. Boccia, Kimberly Bogard, Stephen J. Noga, Robert M. Rifkin, Habte A. Yimer, Sudhir Manda, Haresh S. Jhangiani, Roger M. Lyons, Brittany Demers, Renda H. Ferrari, Suman Kambhampati, Dasha Cherepanov, Ruemu Ejedafeta Birhiray, Veena Charu, Christopher A. Yasenchak, Saulius Girnius, Jack Aiello, Presley Whidden, Vickie Lu
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Background The ongoing US MM-6 study is investigating in-class transition (iCT) from parenteral bortezomib-based induction to all-oral ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) with the aim of increasing proteasome inhibitor (PI)-based treatm